<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03500484</url>
  </required_header>
  <id_info>
    <org_study_id>2000022407</org_study_id>
    <nct_id>NCT03500484</nct_id>
  </id_info>
  <brief_title>Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.</brief_title>
  <official_title>Effect of Liraglutide on Neural Responses to High Fructose Corn Syrup in Individuals With Obesity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yale University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effects of liraglutide on neural responses to high fructose corn syrup (HFCS) in&#xD;
      individuals with obesity.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Adolescents are the highest consumers of sugar sweetened beverages (SSB) potentially because&#xD;
      their developing brains are most susceptible to the rewarding neural effects of sugar&#xD;
      consumption. Thus, we specifically target this population (adolescents) to understand neural&#xD;
      mechanisms involved in excess sugar consumption which predisposes to the development of&#xD;
      obesity, prediabetes, and type 2 diabetes.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">June 6, 2018</start_date>
  <completion_date type="Anticipated">April 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>15 control and 30 obese subjects</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To investigate brain response in obese young adults who drink sugar sweetened beverages.</measure>
    <time_frame>1 week</time_frame>
    <description>To investigate brain response (using fMRI) to acute consumption of sugar sweetened beverages in obese prediabetic adolescents/young adults (age 18-39 yrs).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>To investigate brain response in obese young adults who drink sugar sweetened beverages.</measure>
    <time_frame>12 weeks</time_frame>
    <description>To investigate brain response (using fMRI) to acute consumption of sugar sweetened drinks in obese prediabetic adolescents/young adults (age 18-39 yrs).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the effect of liraglutide on neural responses.</measure>
    <time_frame>12 weeks</time_frame>
    <description>To investigate the effect of neural responses in obese prediabetic adolescents/young adults.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To investigate the role of specific metabolic/hormonal responses in the setting of liraglutide treatment, in affecting neural responses to sugar ingestion.</measure>
    <time_frame>12 weeks</time_frame>
    <description>To investigate the role of specific metabolic/hormonal responses in the setting of liraglutide treatment, in affecting neural responses to sugar ingestion.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Obesity, Childhood</condition>
  <condition>Neural Development</condition>
  <arm_group>
    <arm_group_label>obese subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects will self-administer Liraglutide once daily for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>lean subjects</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no intervention</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Liraglutide</intervention_name>
    <description>Liraglutide will be supplied in the following package sizes containing disposable, pre-filled, multidose pens. Each individual pen delivers doses of 0.6 mg, 1.2 mg, 1.8 mg, 2.4 mg or 3 mg (6 mg/mL, 3 mL). Liraglutide will be self-administered daily for 12 weeks under the following regimen: 0.6mg for 1 week, 1.2mg for 1 week, 1.8mg for 1 week, 2.4mg for 1 week, 3.0mg until week 12.</description>
    <arm_group_label>obese subjects</arm_group_label>
    <other_name>Glucagon-like peptide 1</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. 18-39 years old&#xD;
&#xD;
          2. Lean (BMI 18.5-24.9 kg/m2) with normoglycemia&#xD;
&#xD;
          3. Obese (BMI 30-45 kg/m2) with or without prediabetes&#xD;
&#xD;
          4. Weight stable&#xD;
&#xD;
          5. Right handed&#xD;
&#xD;
          6. Able to read and write in English&#xD;
&#xD;
          7. Able to provide written and verbal informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current active participation in a weight loss program or weight loss of &gt;=10% of total&#xD;
             body weight during the previous 6 months&#xD;
&#xD;
          2. Prior bariatric surgery or current gastric balloon&#xD;
&#xD;
          3. Weight &gt;440lbs or waist circumference &gt;142cm&#xD;
&#xD;
          4. Following a vegetarian/vegan diet or dieting/restricting food&#xD;
&#xD;
          5. Significant medical condition&#xD;
&#xD;
          6. Current use of weight-loss medications or supplements, psychiatric medications or&#xD;
             anti- hyperglycemic medications&#xD;
&#xD;
          7. History of or family history of multiple endocrine neoplasia type 1 (MEN-I) or&#xD;
             medullary thyroid cancer, alcoholism, or previous history of pancreatitis&#xD;
&#xD;
          8. Females who are pregnant or lactating, or who are unwilling to use proper&#xD;
             contraception or remain abstinent,&#xD;
&#xD;
          9. Claustrophobia that would interfere with MRI or metal in their body that would pose a&#xD;
             risk in the MRI.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ania Jastreboff, Phd,MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Yale University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Yale University</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06511</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>April 9, 2018</study_first_submitted>
  <study_first_submitted_qc>April 9, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2018</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Pediatric Obesity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Liraglutide</mesh_term>
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

